Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementTreatment of Acute Myeloid Leukemia in Adolescent and Young Adult PatientsBeyond hypomethylating agents failure in patients with myelodysplastic syndromesNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeCurrent and emerging strategies for the prevention of graft-versus-host diseaseClinical Results of Hypomethylating Agents in AML TreatmentAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Novel therapeutic options in Acute Myeloid LeukemiaOutcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Implementation of adaptive methods in early-phase clinical trials.Evaluation of BM cytomorphology after allo-SCT in patients with AML.Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Phase I design for completely or partially ordered treatment schedules.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibComparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasIncreasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Decitabine for acute myeloid leukemia.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Acute myeloid leukemia: 2014 update on risk-stratification and management.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationNational Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committeeCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.
P2860
Q26770391-3D79C347-99F8-491A-BCB5-A333EF629A1DQ26796240-84756167-8722-4CF1-9B85-54F9037213ADQ26799609-663B9BFF-7BB0-4CBA-96EF-D8B7857414BCQ26827079-4CC2643B-A7DA-4AD8-B3CB-F2460FE5243EQ26829132-78C75008-FF73-4C33-BE56-F06FC6814AA8Q27016541-2B5EF82B-F031-4B17-8419-92D4D5E9DC78Q27022725-51FFEBE0-FF62-4576-84B4-9A494960F1FFQ27851694-26BE899D-9F7C-4016-B79D-39EF1CD4CBE4Q28069889-71E08FF7-5272-4F06-A9C8-9408BBB98939Q30240140-3337FB39-AA49-45D5-B040-925E5D91A5A0Q30274942-B11DE935-9451-4CDB-8F5E-B0C093CE15E9Q30277243-3EA96A25-74DF-4542-951D-23F4FAA6ABD1Q30318110-F870783B-A712-496A-BF74-B20581B8BDA8Q30399209-D3AD0671-757E-4FC1-A987-6074E5F270D7Q30407970-0D245341-E445-4991-B37A-B368823064EDQ33405278-B5E8A689-3EB5-41BF-BB9A-5733B0F7231BQ33737884-5CE93695-DBD6-46CF-8735-AAB41F11EDC0Q33772438-E5CE8B1C-F297-4864-8410-4C2964D554FAQ33830964-14A2EE3E-0CF5-455D-AF54-67BC078D3FC0Q33850163-B4EE8201-28AE-45FF-938D-4CB3D9025ED3Q33905443-9CDECFDF-B9B0-4991-B1D5-3E0A78589A8EQ33931553-26C1E85A-F9B0-4748-933E-332408167F99Q33978951-A78A9DFA-8236-4319-A3AF-32A6DF3CFF89Q34257184-F671BFE9-7542-4128-BEC8-6DC5298CCFA4Q34273735-701A475C-9ADD-4207-8EC2-34A4D36D67A6Q34325183-BA0627D1-9C3F-43DB-A28A-78DD6CC0AE60Q34350209-16E202C7-42BB-486B-A21C-1BE235130271Q34380489-593651E5-48C6-40F1-8573-29DE4A70D695Q34665691-0F96A754-2D7A-4444-947C-625053CE04BEQ34667051-A1C62A6F-1430-4A1A-A70A-32A7FA52C85FQ34861985-4859F524-E5E6-4124-AD16-B7DC6CFD69CCQ35008021-CFA4C077-C38C-4068-8F3D-078F39CFDB1CQ35546759-20AFF9F0-300C-4111-AE98-140A4B1DBFCEQ35613049-3B6717F0-D8B5-4D53-B93E-9F8997C65461Q35641272-554BC3BC-6682-45CE-9BBF-59890CEB90E7Q35835657-F78AD5E0-F061-4AC2-8F3D-1B997F12272EQ35854094-421EE17B-5AB1-4C5D-BAF5-F443B2D7D30CQ36036263-3055C478-E34F-4006-8A20-416ABC85208CQ36055095-937D5180-D8A1-46EC-A3E7-ACE25DC4C1E3Q36203084-76554076-534F-4B51-BC84-7DAB89AF47C5
P2860
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Maintenance therapy with low-d ...... se and schedule finding study.
@ast
Maintenance therapy with low-d ...... se and schedule finding study.
@en
type
label
Maintenance therapy with low-d ...... se and schedule finding study.
@ast
Maintenance therapy with low-d ...... se and schedule finding study.
@en
prefLabel
Maintenance therapy with low-d ...... se and schedule finding study.
@ast
Maintenance therapy with low-d ...... se and schedule finding study.
@en
P2093
P2860
P50
P356
P1433
P1476
Maintenance therapy with low-d ...... se and schedule finding study.
@en
P2093
Hoang Q Nguyen
Leandro de Padua Silva
Marcos de Lima
Peter F Thall
Richard Champlin
Roy B Jones
Thomas M Braun
P2860
P304
P356
10.1002/CNCR.25500
P407
P577
2010-07-29T00:00:00Z